Cargando…
Measurable residual disease assessed by mass spectrometry in peripheral blood in multiple myeloma in a phase II trial of carfilzomib, lenalidomide, dexamethasone and autologous stem cell transplantation
| Autores principales: | , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group UK
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7873068/ https://www.ncbi.nlm.nih.gov/pubmed/33563912 http://dx.doi.org/10.1038/s41408-021-00418-2 |
| _version_ | 1783649316724801536 |
|---|---|
| author | Derman, Benjamin A. Stefka, Andrew T. Jiang, Ken McIver, Amanda Kubicki, Tadeusz Jasielec, Jagoda K. Jakubowiak, Andrzej J. |
| author_facet | Derman, Benjamin A. Stefka, Andrew T. Jiang, Ken McIver, Amanda Kubicki, Tadeusz Jasielec, Jagoda K. Jakubowiak, Andrzej J. |
| author_sort | Derman, Benjamin A. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-7873068 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2021 |
| publisher | Nature Publishing Group UK |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-78730682021-02-16 Measurable residual disease assessed by mass spectrometry in peripheral blood in multiple myeloma in a phase II trial of carfilzomib, lenalidomide, dexamethasone and autologous stem cell transplantation Derman, Benjamin A. Stefka, Andrew T. Jiang, Ken McIver, Amanda Kubicki, Tadeusz Jasielec, Jagoda K. Jakubowiak, Andrzej J. Blood Cancer J Correspondence Nature Publishing Group UK 2021-02-05 /pmc/articles/PMC7873068/ /pubmed/33563912 http://dx.doi.org/10.1038/s41408-021-00418-2 Text en © The Author(s) 2021 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. |
| spellingShingle | Correspondence Derman, Benjamin A. Stefka, Andrew T. Jiang, Ken McIver, Amanda Kubicki, Tadeusz Jasielec, Jagoda K. Jakubowiak, Andrzej J. Measurable residual disease assessed by mass spectrometry in peripheral blood in multiple myeloma in a phase II trial of carfilzomib, lenalidomide, dexamethasone and autologous stem cell transplantation |
| title | Measurable residual disease assessed by mass spectrometry in peripheral blood in multiple myeloma in a phase II trial of carfilzomib, lenalidomide, dexamethasone and autologous stem cell transplantation |
| title_full | Measurable residual disease assessed by mass spectrometry in peripheral blood in multiple myeloma in a phase II trial of carfilzomib, lenalidomide, dexamethasone and autologous stem cell transplantation |
| title_fullStr | Measurable residual disease assessed by mass spectrometry in peripheral blood in multiple myeloma in a phase II trial of carfilzomib, lenalidomide, dexamethasone and autologous stem cell transplantation |
| title_full_unstemmed | Measurable residual disease assessed by mass spectrometry in peripheral blood in multiple myeloma in a phase II trial of carfilzomib, lenalidomide, dexamethasone and autologous stem cell transplantation |
| title_short | Measurable residual disease assessed by mass spectrometry in peripheral blood in multiple myeloma in a phase II trial of carfilzomib, lenalidomide, dexamethasone and autologous stem cell transplantation |
| title_sort | measurable residual disease assessed by mass spectrometry in peripheral blood in multiple myeloma in a phase ii trial of carfilzomib, lenalidomide, dexamethasone and autologous stem cell transplantation |
| topic | Correspondence |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7873068/ https://www.ncbi.nlm.nih.gov/pubmed/33563912 http://dx.doi.org/10.1038/s41408-021-00418-2 |
| work_keys_str_mv | AT dermanbenjamina measurableresidualdiseaseassessedbymassspectrometryinperipheralbloodinmultiplemyelomainaphaseiitrialofcarfilzomiblenalidomidedexamethasoneandautologousstemcelltransplantation AT stefkaandrewt measurableresidualdiseaseassessedbymassspectrometryinperipheralbloodinmultiplemyelomainaphaseiitrialofcarfilzomiblenalidomidedexamethasoneandautologousstemcelltransplantation AT jiangken measurableresidualdiseaseassessedbymassspectrometryinperipheralbloodinmultiplemyelomainaphaseiitrialofcarfilzomiblenalidomidedexamethasoneandautologousstemcelltransplantation AT mciveramanda measurableresidualdiseaseassessedbymassspectrometryinperipheralbloodinmultiplemyelomainaphaseiitrialofcarfilzomiblenalidomidedexamethasoneandautologousstemcelltransplantation AT kubickitadeusz measurableresidualdiseaseassessedbymassspectrometryinperipheralbloodinmultiplemyelomainaphaseiitrialofcarfilzomiblenalidomidedexamethasoneandautologousstemcelltransplantation AT jasielecjagodak measurableresidualdiseaseassessedbymassspectrometryinperipheralbloodinmultiplemyelomainaphaseiitrialofcarfilzomiblenalidomidedexamethasoneandautologousstemcelltransplantation AT jakubowiakandrzejj measurableresidualdiseaseassessedbymassspectrometryinperipheralbloodinmultiplemyelomainaphaseiitrialofcarfilzomiblenalidomidedexamethasoneandautologousstemcelltransplantation |